Last edition
News about "Xgeva biosimilar"
US FDA Approves Teva's Denosumab Biosimilar DEGEVM
Teva’s DEGEVMA, a denosumab biosimilar to Xgeva, has gained US FDA approval for cancer-related bone complications and other indications.
Xgeva Biosimilar | 30/09/2026 | By News Bureau | 305
Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US
Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.
Xgeva Biosimilar | 08/04/2026 | By News Bureau | 189
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy